Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate - Motif mutation of hepatitis B virus after long-term lamivudine therapy

Clinical Infectious Diseases

Volumn 33, Issue 3, 2001, Pages 403-405

  Kim, Jin Wook ^a   Lee, Hyo Suk ^a   Woo, Gwang Hoon ^a   Yoon, Jung Hwan ^a   Jang, Ja June ^b   Chi, Je Geun ^b   Kim, Chung Yong ^a  

^a Department of Internal Medicine and Liver Research Institute ^*  (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASPARTIC ACID; LAMIVUDINE; METHIONINE; TYROSINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; DISEASE EXACERBATION; FATALITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER NECROSIS; LONG TERM CARE; MALE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

AMINO ACID MOTIFS; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; FATAL OUTCOME; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPETENCE; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; NECROSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034919416     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321879     Document Type: Article

References (10)

1. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
2. A one-year trial of lamivudine for chronic hepatitis B
3. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
4. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
5. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
6. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
7. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
8. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir nonresponse, followed by lamivudine resistance resulting in graft loss
9. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
10. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants